SEQENS is a worldwide leader in pharmaceutical solutions and specialty ingredients.
The group generates a revenue of 1.1 MM€ and operates 16 manufacturing plants and 9 R&D centers in Europe, North America and Asia. 3,300 employees contribute to the success of SEQENS, among which 350 scientists, engineers and experts who develop tailor-made solutions for our customers.
SEQENS is an integrated player offering a broad portfolio of active ingredients, pharmaceutical intermediates and specialty ingredients. We develop and industrialize the most demanding molecules, and rely on our ability to innovate, develop and implement the best available technologies.
Company Details
- Employees
- 1.32K
- Founded
- -
- Address
- 21, Chemin De La Sauvegarde, Écully,auvergne-Rhône-Alpes 69130,france
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- seqens.com
- Keywords
- Pharmaceutical Synthesis, Specialty Ingredients, Cosmetics, Custom Specialties, R&D, CDMO, CRDO, Generics, Innovative Pharmaceuticals, Personnal Care.
- HQ
- Écully, Auvergne-Rhône-Alpes
Seqens Questions
Seqens's website is seqens.com
Seqens's LinkedIn profile is https://fr.linkedin.com/company/seqens
Seqens has
1.32K employees.
View email and phone details for 1.32K
employees at Seqens.
Seqens's industry is
Pharmaceutical Manufacturing
Seqens's top competitors are
Biogaran,
Euroapi,
Servier,
Lfb,
Cellforcure By Seqens,
Ipsophene,
Gsk,
Seqens Pharmaceutical Solutions,
Pierre Fabre Laboratories,
Sanofi.
Seqens's categories are Pharmaceutical Manufacturing
Seqens's founding year is 2003
